AVALIAÇÃO DO EFEITO DE LEVAMISOL SOBRE A MORFOLOGIA E MULTIPLICAÇÃO DE TRYPANOSOMA CRUZI
Autor(a) principal: | |
---|---|
Data de Publicação: | 2023 |
Tipo de documento: | Trabalho de conclusão de curso |
Idioma: | por |
Título da fonte: | Repositório Institucional da UFMS |
Texto Completo: | https://repositorio.ufms.br/handle/123456789/7686 |
Resumo: | The protozoan Trypanosoma cruzi is the etiological agent of Chagas Disease, one of the diseases considered by the World Health Organization to be neglected. The parasite has the ability to cause parasitemia and eventually invade tissues. The drugs used to treat this disease are effective, but cause many adverse effects, which is why adherence to treatment is low. Faced with this scenario, there is a search for pharmacotherapeutic alternatives, but this path comes up against common barriers to the discovery of new drugs, such as time and resources. For this reason, drug repositioning is a viable alternative, as it requires less time and/or resources. Levamisole is a drug from the anthelmintic class, with an immunomodulatory effect, used to treat ascariasis. Recent articles also point to its activity in forms of Giardia sp. Its mechanism of action is throughenzymatic interference in the parasite and, because of this, the possibility of it having activity against strains of Trypanosoma cruzi is being investigated. The drug’s activity was assessed in three ways: through the MTS test, with a concentration of 200ug/mL of the drug and incubation at 37°C for 72 hours; counting parasites in a Neubauer chamber with a concentration of 400ug/mL of the drug; and analyzing the morphologyof the protozoa using a microscope slide fixed with 4% paraformaldehyde and stainedusing the Panocyte method. A culture without the addition of the drug was used as a control for the three methods. Parasite growth was checked at 24 hours and 72 hours and, at the end, a morphological analysis was carried out. Based on the results of the tests, the interaction between the drug and the parasite was evaluated. Based on this evaluation, it will be possible in the future to determine the effect of this drug as an immunomodulator in cells infected with the parasite. |
id |
UFMS_81e7ba01fda215504c9ca377582b9c38 |
---|---|
oai_identifier_str |
oai:repositorio.ufms.br:123456789/7686 |
network_acronym_str |
UFMS |
network_name_str |
Repositório Institucional da UFMS |
repository_id_str |
2124 |
spelling |
2023-12-03T21:13:20Z2023-12-03T21:13:20Z2023https://repositorio.ufms.br/handle/123456789/7686The protozoan Trypanosoma cruzi is the etiological agent of Chagas Disease, one of the diseases considered by the World Health Organization to be neglected. The parasite has the ability to cause parasitemia and eventually invade tissues. The drugs used to treat this disease are effective, but cause many adverse effects, which is why adherence to treatment is low. Faced with this scenario, there is a search for pharmacotherapeutic alternatives, but this path comes up against common barriers to the discovery of new drugs, such as time and resources. For this reason, drug repositioning is a viable alternative, as it requires less time and/or resources. Levamisole is a drug from the anthelmintic class, with an immunomodulatory effect, used to treat ascariasis. Recent articles also point to its activity in forms of Giardia sp. Its mechanism of action is throughenzymatic interference in the parasite and, because of this, the possibility of it having activity against strains of Trypanosoma cruzi is being investigated. The drug’s activity was assessed in three ways: through the MTS test, with a concentration of 200ug/mL of the drug and incubation at 37°C for 72 hours; counting parasites in a Neubauer chamber with a concentration of 400ug/mL of the drug; and analyzing the morphologyof the protozoa using a microscope slide fixed with 4% paraformaldehyde and stainedusing the Panocyte method. A culture without the addition of the drug was used as a control for the three methods. Parasite growth was checked at 24 hours and 72 hours and, at the end, a morphological analysis was carried out. Based on the results of the tests, the interaction between the drug and the parasite was evaluated. Based on this evaluation, it will be possible in the future to determine the effect of this drug as an immunomodulator in cells infected with the parasite.O protozoário Trypanosoma cruzi é o agente etiológico da Doença de Chagas, uma das doenças consideradas pela Organização Mundial da Saúde como negligenciadas. O parasito tem a capacidade de causar parasitemia e, eventualmente, invadir tecidos. Os medicamentos destinados ao tratamento para essa doença são eficazes, mas causam muitos efeitos adversos, por isso a adesão ao tratamento é baixa. Diante desse cenário, há a busca por alternativas farmacoterapêuticas, porém esse caminho esbarra em barreiras comuns à descoberta de novos medicamentos, como tempo e recursos. Por isso, o reposicionamento de fármacos se mostra uma alternativa viável, pois demanda menos tempo e/ou recursos. O levamisol é um medicamento da classe dos anti-helmínticos, com efeito imunomodulador, usado para o tratamento de ascaridíase. Artigos recentes ainda apontam sua atividade em formas de Giardia sp. Seu mecanismo de ação se dá por interferência enzimática no parasito e, por causa disso, investiga-se a possibilidade de ter atividade contra cepas de Trypanosoma cruzi. A atividade do fármaco foi avaliada de três formas: através de teste com MTS, com a concentração de 200ug/mL do fármaco e incubação a 37°C por 72 horas; contagem de parasitos emcâmara de Neubauer com concentração de 400ug/mL do fármaco; e análise da morfologia do protozoário através de lâmina de microscopia fixada com paraformaldeído a 4% e corada pelo método Panócito. Como controle, para os três métodos, foi utilizada cultura sem adição do fármaco. O crescimento do parasito foi verificado em 24 horas e em 72 horas e, ao final, foi feita a análise morfológica. A partir dos resultados dos testes foi avaliada a interação desse fármaco com o parasito. Com base nessa avaliação, será possível, futuramente, estipular o efeito desse fármaco como imunomodulador em células infectadas com o parasito.Fundação Universidade Federal de Mato Grosso do SulUFMSCiências BiológicasTrypanosoma cruziLevamisolDoença de Chagas.AVALIAÇÃO DO EFEITO DE LEVAMISOL SOBRE A MORFOLOGIA E MULTIPLICAÇÃO DE TRYPANOSOMA CRUZIinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/bachelorThesisALDA MARIA TEIXEIRA FERREIRAMILENA PEREIRA BATISTAinfo:eu-repo/semantics/openAccessporreponame:Repositório Institucional da UFMSinstname:Universidade Federal de Mato Grosso do Sul (UFMS)instacron:UFMSORIGINAL9032.pdf9032.pdfapplication/pdf918845https://repositorio.ufms.br/bitstream/123456789/7686/-1/9032.pdf6e6fb2bc7ca121bde0801849dccc1a51MD5-1123456789/76862023-12-03 17:13:20.905oai:repositorio.ufms.br:123456789/7686Repositório InstitucionalPUBhttps://repositorio.ufms.br/oai/requestri.prograd@ufms.bropendoar:21242023-12-03T21:13:20Repositório Institucional da UFMS - Universidade Federal de Mato Grosso do Sul (UFMS)false |
dc.title.pt_BR.fl_str_mv |
AVALIAÇÃO DO EFEITO DE LEVAMISOL SOBRE A MORFOLOGIA E MULTIPLICAÇÃO DE TRYPANOSOMA CRUZI |
title |
AVALIAÇÃO DO EFEITO DE LEVAMISOL SOBRE A MORFOLOGIA E MULTIPLICAÇÃO DE TRYPANOSOMA CRUZI |
spellingShingle |
AVALIAÇÃO DO EFEITO DE LEVAMISOL SOBRE A MORFOLOGIA E MULTIPLICAÇÃO DE TRYPANOSOMA CRUZI MILENA PEREIRA BATISTA Trypanosoma cruzi Levamisol Doença de Chagas. Ciências Biológicas |
title_short |
AVALIAÇÃO DO EFEITO DE LEVAMISOL SOBRE A MORFOLOGIA E MULTIPLICAÇÃO DE TRYPANOSOMA CRUZI |
title_full |
AVALIAÇÃO DO EFEITO DE LEVAMISOL SOBRE A MORFOLOGIA E MULTIPLICAÇÃO DE TRYPANOSOMA CRUZI |
title_fullStr |
AVALIAÇÃO DO EFEITO DE LEVAMISOL SOBRE A MORFOLOGIA E MULTIPLICAÇÃO DE TRYPANOSOMA CRUZI |
title_full_unstemmed |
AVALIAÇÃO DO EFEITO DE LEVAMISOL SOBRE A MORFOLOGIA E MULTIPLICAÇÃO DE TRYPANOSOMA CRUZI |
title_sort |
AVALIAÇÃO DO EFEITO DE LEVAMISOL SOBRE A MORFOLOGIA E MULTIPLICAÇÃO DE TRYPANOSOMA CRUZI |
author |
MILENA PEREIRA BATISTA |
author_facet |
MILENA PEREIRA BATISTA |
author_role |
author |
dc.contributor.advisor1.fl_str_mv |
ALDA MARIA TEIXEIRA FERREIRA |
dc.contributor.author.fl_str_mv |
MILENA PEREIRA BATISTA |
contributor_str_mv |
ALDA MARIA TEIXEIRA FERREIRA |
dc.subject.por.fl_str_mv |
Trypanosoma cruzi Levamisol Doença de Chagas. |
topic |
Trypanosoma cruzi Levamisol Doença de Chagas. Ciências Biológicas |
dc.subject.classification.pt_BR.fl_str_mv |
Ciências Biológicas |
description |
The protozoan Trypanosoma cruzi is the etiological agent of Chagas Disease, one of the diseases considered by the World Health Organization to be neglected. The parasite has the ability to cause parasitemia and eventually invade tissues. The drugs used to treat this disease are effective, but cause many adverse effects, which is why adherence to treatment is low. Faced with this scenario, there is a search for pharmacotherapeutic alternatives, but this path comes up against common barriers to the discovery of new drugs, such as time and resources. For this reason, drug repositioning is a viable alternative, as it requires less time and/or resources. Levamisole is a drug from the anthelmintic class, with an immunomodulatory effect, used to treat ascariasis. Recent articles also point to its activity in forms of Giardia sp. Its mechanism of action is throughenzymatic interference in the parasite and, because of this, the possibility of it having activity against strains of Trypanosoma cruzi is being investigated. The drug’s activity was assessed in three ways: through the MTS test, with a concentration of 200ug/mL of the drug and incubation at 37°C for 72 hours; counting parasites in a Neubauer chamber with a concentration of 400ug/mL of the drug; and analyzing the morphologyof the protozoa using a microscope slide fixed with 4% paraformaldehyde and stainedusing the Panocyte method. A culture without the addition of the drug was used as a control for the three methods. Parasite growth was checked at 24 hours and 72 hours and, at the end, a morphological analysis was carried out. Based on the results of the tests, the interaction between the drug and the parasite was evaluated. Based on this evaluation, it will be possible in the future to determine the effect of this drug as an immunomodulator in cells infected with the parasite. |
publishDate |
2023 |
dc.date.accessioned.fl_str_mv |
2023-12-03T21:13:20Z |
dc.date.available.fl_str_mv |
2023-12-03T21:13:20Z |
dc.date.issued.fl_str_mv |
2023 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/bachelorThesis |
format |
bachelorThesis |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://repositorio.ufms.br/handle/123456789/7686 |
url |
https://repositorio.ufms.br/handle/123456789/7686 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.publisher.none.fl_str_mv |
Fundação Universidade Federal de Mato Grosso do Sul |
dc.publisher.initials.fl_str_mv |
UFMS |
dc.publisher.country.pt_BR.fl_str_mv |
|
publisher.none.fl_str_mv |
Fundação Universidade Federal de Mato Grosso do Sul |
dc.source.none.fl_str_mv |
reponame:Repositório Institucional da UFMS instname:Universidade Federal de Mato Grosso do Sul (UFMS) instacron:UFMS |
instname_str |
Universidade Federal de Mato Grosso do Sul (UFMS) |
instacron_str |
UFMS |
institution |
UFMS |
reponame_str |
Repositório Institucional da UFMS |
collection |
Repositório Institucional da UFMS |
bitstream.url.fl_str_mv |
https://repositorio.ufms.br/bitstream/123456789/7686/-1/9032.pdf |
bitstream.checksum.fl_str_mv |
6e6fb2bc7ca121bde0801849dccc1a51 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 |
repository.name.fl_str_mv |
Repositório Institucional da UFMS - Universidade Federal de Mato Grosso do Sul (UFMS) |
repository.mail.fl_str_mv |
ri.prograd@ufms.br |
_version_ |
1815448015623684096 |